1
|
Huszár J, Bozó É, Beke G, Szalai KK, Kardos P, Boros A, Greiner I, Éles J. hERG optimization of MCHR1 antagonist benzofuro-pyridine and pyrazino-indole derivatives. ChemMedChem 2022; 17:e202100707. [PMID: 35041296 DOI: 10.1002/cmdc.202100707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Revised: 12/21/2021] [Indexed: 11/09/2022]
Abstract
Obesity is a global epidemic associated with multiple severe diseases. Several pharmacotherapies have been investigated including the antagonists of melanin concentrating hormone receptor 1 (MCHR1). The design, synthesis, and biological studies of novel MCHR1 antagonists based on benzofuro-pyridine and pyrazino-indole scaffold was performed. We confirmed that fine-tuning lipophilicity and basic pKa by modifying the benzyl-group and introducing different substituents on the aliphatic nitrogen sidechain decreases both hERG inhibition and metabolic clearance. We have succeeded to develop excellent in vitro parameters in case of compounds 17 and 23g , that can be considered as valuable tools for further pharmacological investigation.
Collapse
Affiliation(s)
- József Huszár
- Gedeon Richter PLc., Department of chemistry, Gyömrői út 19-21, 1103, Budapest, HUNGARY
| | - Éva Bozó
- Gedeon Richter Nyrt, Department of Chemistry, HUNGARY
| | - Gyula Beke
- Gedeon Richter Nyrt, Department of Chemistry, HUNGARY
| | | | - Péter Kardos
- Gedeon Richter Nyrt, Pharmacological and Drug Safety Research, HUNGARY
| | - András Boros
- Gedeon Richter Nyrt, Pharmacological and Drug Safety Research, HUNGARY
| | | | - János Éles
- Gedeon Richter Nyrt, Department of Chemistry, HUNGARY
| |
Collapse
|
2
|
MCH-R1 Antagonist GPS18169, a Pseudopeptide, Is a Peripheral Anti-Obesity Agent in Mice. Molecules 2021; 26:molecules26051291. [PMID: 33673598 PMCID: PMC7957705 DOI: 10.3390/molecules26051291] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Revised: 02/17/2021] [Accepted: 02/22/2021] [Indexed: 01/01/2023] Open
Abstract
Melanin-concentrating hormone (MCH) is a 19 amino acid long peptide found in the brain of animals, including fishes, batrachians, and mammals. MCH is implicated in appetite and/or energy homeostasis. Antagonists at its receptor (MCH-R1) could be major tools (or ultimately drugs) to understand the mechanism of MCH action and to fight the obesity syndrome that is a worldwide societal health problem. Ever since the deorphanisation of the MCH receptor, we cloned, expressed, and characterized the receptor MCH-R1 and started a vast medicinal chemistry program aiming at the discovery of such usable compounds. In the present final work, we describe GPS18169, a pseudopeptide antagonist at the MCH-R1 receptor with an affinity in the nanomolar range and a Ki for its antagonistic effect in the 20 picomolar range. Its metabolic stability is rather ameliorated compared to its initial parent compound, the antagonist S38151. We tested it in an in vivo experiment using high diet mice. GPS18169 was found to be active in limiting the accumulation of adipose tissues and, correlatively, we observed a normalization of the insulin level in the treated animals, while no change in food or water consumption was observed.
Collapse
|
3
|
Ahmad S, Washburn WN, Hernandez AS, Bisaha S, Ngu K, Wang W, Pelleymounter MA, Longhi D, Flynn N, Azzara AV, Rohrbach K, Devenny J, Rooney S, Thomas M, Glick S, Godonis H, Harvey S, Zhang H, Gemzik B, Janovitz EB, Huang C, Zhang L, Robl JA, Murphy BJ. Synthesis and Antiobesity Properties of 6-(4-Chlorophenyl)-3-(4-((3,3-difluoro-1-hydroxycyclobutyl)methoxy)-3-methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one (BMS-814580): A Highly Efficacious Melanin Concentrating Hormone Receptor 1 (MCHR1) Inhibitor. J Med Chem 2016; 59:8848-8858. [DOI: 10.1021/acs.jmedchem.6b00676] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Saleem Ahmad
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - William N. Washburn
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Andres S. Hernandez
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Sharon Bisaha
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Khehyong Ngu
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Wei Wang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Mary Ann Pelleymounter
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Daniel Longhi
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Neil Flynn
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Anthony V. Azzara
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Kenneth Rohrbach
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - James Devenny
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Suzanne Rooney
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Michael Thomas
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Susan Glick
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Helen Godonis
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Susan Harvey
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Hongwei Zhang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Brian Gemzik
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Evan B. Janovitz
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Christine Huang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Lisa Zhang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Jeffrey A. Robl
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Brian J. Murphy
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §PCO MAP, ∥PCO Discovery Toxicology, and ⊥PCO Bioanalytical Research, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| |
Collapse
|
4
|
Evolution of physicochemical properties of melanin concentrating hormone receptor 1 (MCHr1) antagonists. Bioorg Med Chem Lett 2016; 26:4559-4564. [PMID: 27595423 DOI: 10.1016/j.bmcl.2016.08.072] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2016] [Revised: 08/12/2016] [Accepted: 08/20/2016] [Indexed: 02/07/2023]
Abstract
One pharmacological principle for the treatment of obesity is blockade of the melanin concentrating hormone receptor 1 (MCHr1), which in rodents has been shown to be strongly associated with food intake and energy expenditure. However, discovery of safe and efficacious MCHr1 antagonists has proved to be complex. So far, six compounds have been progressed into clinical trials, but clinical validation of the concept is still lacking. An account of discovery of the three most recent clinical candidates targeting the MCHr1 receptor is given, with an emphasis on their physicochemical properties.
Collapse
|
5
|
Johansson A, Löfberg C, Antonsson M, von Unge S, Hayes MA, Judkins R, Ploj K, Benthem L, Lindén D, Brodin P, Wennerberg M, Fredenwall M, Li L, Persson J, Bergman R, Pettersen A, Gennemark P, Hogner A. Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties. J Med Chem 2016; 59:2497-511. [PMID: 26741166 DOI: 10.1021/acs.jmedchem.5b01654] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
A novel series of melanin concentrating hormone receptor 1 (MCHr1) antagonists were the starting point for a drug discovery program that culminated in the discovery of 103 (AZD1979). The lead optimization program was conducted with a focus on reducing lipophilicity and understanding the physicochemical properties governing CNS exposure and undesired off-target pharmacology such as hERG interactions. An integrated approach was taken where the key assay was ex vivo receptor occupancy in mice. The candidate compound 103 displayed appropriate lipophilicity for a CNS indication and showed excellent permeability with no efflux. Preclinical GLP toxicology and safety pharmacology studies were without major findings and 103 was taken into clinical trials.
Collapse
Affiliation(s)
- Anders Johansson
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Christian Löfberg
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Madeleine Antonsson
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Sverker von Unge
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Martin A Hayes
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Robert Judkins
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Karolina Ploj
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Lambertus Benthem
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Daniel Lindén
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Peter Brodin
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Marie Wennerberg
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Marléne Fredenwall
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Lanna Li
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Joachim Persson
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Rolf Bergman
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Anna Pettersen
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Peter Gennemark
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| | - Anders Hogner
- Cardiovascular & Metabolic Diseases iMed and ‡Global Medicines Development, AstraZeneca Gothenburg , 431 83 Mölndal, Sweden
| |
Collapse
|
6
|
Karlsson S, Bergman R, Löfberg C, Moore PR, Pontén F, Tholander J, Sörensen H. Development of a Large-Scale Route to an MCH1 Receptor Antagonist: Investigation of a Staudinger Ketene–Imine Cycloaddition in Batch and Flow Mode. Org Process Res Dev 2015. [DOI: 10.1021/acs.oprd.5b00319] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Staffan Karlsson
- Medicinal Chemistry, Cardiovascular & Metabolic Diseases iMed, AstraZeneca R & D, Mölndal SE-431 83, Sweden
| | - Rolf Bergman
- Medicinal Chemistry, Cardiovascular & Metabolic Diseases iMed, AstraZeneca R & D, Mölndal SE-431 83, Sweden
| | - Christian Löfberg
- Medicinal Chemistry, Cardiovascular & Metabolic Diseases iMed, AstraZeneca R & D, Mölndal SE-431 83, Sweden
| | - Peter R. Moore
- Global Chemical Development, AstraZeneca R & D, Macclesfield SK10 4NX, United Kingdom
| | - Fritiof Pontén
- Medicinal Chemistry, Cardiovascular & Metabolic Diseases iMed, AstraZeneca R & D, Mölndal SE-431 83, Sweden
| | - Joakim Tholander
- Medicinal Chemistry, Cardiovascular & Metabolic Diseases iMed, AstraZeneca R & D, Mölndal SE-431 83, Sweden
| | - Henrik Sörensen
- Medicinal Chemistry, Cardiovascular & Metabolic Diseases iMed, AstraZeneca R & D, Mölndal SE-431 83, Sweden
| |
Collapse
|
7
|
Müller SG, Heckel A, Kley JT, Lehmann T, Lustenberger P, Oost T, Roth GJ, Rudolf K, Arndt K, Lenter M, Lotz RR, Maier GM, Markert M, Schindler M, Stenkamp D. Design, synthesis and evaluation of MCH receptor 1 antagonists—Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414. Bioorg Med Chem Lett 2015; 25:3264-9. [DOI: 10.1016/j.bmcl.2015.05.077] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2015] [Revised: 05/22/2015] [Accepted: 05/24/2015] [Indexed: 12/14/2022]
|
8
|
Roth GJ, Heckel A, Kley JT, Lehmann T, Müller SG, Oost T, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RRH, Schindler M, Thomas L, Stenkamp D. Design, synthesis and evaluation of MCH receptor 1 antagonists--Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition. Bioorg Med Chem Lett 2015; 25:3270-4. [PMID: 26077492 DOI: 10.1016/j.bmcl.2015.05.074] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2015] [Revised: 05/22/2015] [Accepted: 05/24/2015] [Indexed: 10/23/2022]
Abstract
Despite recent success there remains a high therapeutic need for the development of drugs targeting diseases associated with the metabolic syndrome. As part of our search for safe and effective MCH-R1 antagonists for the treatment of obesity, a series of 3,6-disubstituted pyridazines was evaluated. During optimization several issues of the initial lead structures had to be resolved, such as selectivity over related GPCRs, inhibition of the hERG channel as well as the potential to induce phospholipidosis. Utilizing property-based design, we could demonstrate that all parameters can significantly be improved by consequently increasing the polarity of the compounds. By this strategy, we succeeded in identifying potent and orally available MCH-R1 antagonists with good selectivity over M1 and 5-HT2A and an improved safety profile with respect to hERG inhibition and phospholipidosis.
Collapse
Affiliation(s)
- Gerald J Roth
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany.
| | - Armin Heckel
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Jörg T Kley
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Thorsten Lehmann
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Stephan G Müller
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Thorsten Oost
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Klaus Rudolf
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Kirsten Arndt
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Cardiometabolic Research, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Ralph Budzinski
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Cardiometabolic Research, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Martin Lenter
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Cardiometabolic Research, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Ralf R H Lotz
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Drug Discovery Support, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Marcus Schindler
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Cardiometabolic Research, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Leo Thomas
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Cardiometabolic Research, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Dirk Stenkamp
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| |
Collapse
|
9
|
Oost T, Heckel A, Kley JT, Lehmann T, Müller S, Roth GJ, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RRH, Maier GM, Markert M, Thomas L, Stenkamp D. Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908. Bioorg Med Chem Lett 2015; 25:3275-80. [PMID: 26105194 DOI: 10.1016/j.bmcl.2015.05.065] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2015] [Revised: 05/22/2015] [Accepted: 05/24/2015] [Indexed: 11/24/2022]
Abstract
Although overweight and obesity are highly prevalent conditions, options to treat them are still very limited. As part of our search for safe and effective MCH-R1 antagonists for the treatment of obesity, two series of pyridones and pyridazinones were evaluated. Optimization was aimed at improving DMPK properties by increasing metabolic stability and improving the safety profile by reducing inhibition of the hERG channel and reducing the potential to induce phospholipidosis. Steric shielding of a labile keto moiety with an ortho-methyl group and fine-tuning of the polarity in several parts of the molecule resulted in BI 186908 (11 g), a potent and selective MCH-R1 antagonist with favorable DMPK and CMC properties. Chronic administration of BI 186908 resulted in significant body weight reduction comparable to sibutramine in a 4 week diet-induced obesity model in rats. Based on its favorable safety profile, BI 186908 was advanced to pre-clinical development.
Collapse
Affiliation(s)
- Thorsten Oost
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany.
| | - Armin Heckel
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Jörg T Kley
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Thorsten Lehmann
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Stephan Müller
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Gerald J Roth
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Klaus Rudolf
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Kirsten Arndt
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Cardiometabolic Research, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Ralph Budzinski
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Cardiometabolic Research, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Martin Lenter
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Cardiometabolic Research, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Ralf R H Lotz
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Drug Discovery Support, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Gerd-Michael Maier
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Drug Discovery Support, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Michael Markert
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Drug Discovery Support, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Leo Thomas
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Cardiometabolic Research, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Dirk Stenkamp
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| |
Collapse
|
10
|
Abdel-Magid AF. Melanin-concentrating hormone receptor 1 antagonists for treatment of obesity. ACS Med Chem Lett 2015; 6:367-8. [PMID: 25941549 DOI: 10.1021/acsmedchemlett.5b00077] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2015] [Indexed: 11/29/2022] Open
|
11
|
Rabal O, Amr FI, Oyarzabal J. Novel Scaffold Fingerprint (SFP): Applications in Scaffold Hopping and Scaffold-Based Selection of Diverse Compounds. J Chem Inf Model 2015; 55:1-18. [DOI: 10.1021/ci500542e] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
- Obdulia Rabal
- Small Molecule Discovery Platform, Molecular Therapeutics
Program, Center for Applied Medical Research (CIMA), University of Navarra, Avda. Pio XII 55, E-31008 Pamplona, Spain
| | - Fares Ibrahim Amr
- Small Molecule Discovery Platform, Molecular Therapeutics
Program, Center for Applied Medical Research (CIMA), University of Navarra, Avda. Pio XII 55, E-31008 Pamplona, Spain
| | - Julen Oyarzabal
- Small Molecule Discovery Platform, Molecular Therapeutics
Program, Center for Applied Medical Research (CIMA), University of Navarra, Avda. Pio XII 55, E-31008 Pamplona, Spain
| |
Collapse
|
12
|
|
13
|
Washburn WN, Manfredi M, Devasthale P, Zhao G, Ahmad S, Hernandez A, Robl JA, Wang W, Mignone J, Wang Z, Ngu K, Pelleymounter MA, Longhi D, Zhao R, Wang B, Huang N, Flynn N, Azzara AV, Barrish JC, Rohrbach K, Devenny JJ, Rooney S, Thomas M, Glick S, Godonis HE, Harvey SJ, Cullen MJ, Zhang H, Caporuscio C, Stetsko P, Grubb M, Maxwell BD, Yang H, Apedo A, Gemzik B, Janovitz EB, Huang C, Zhang L, Freeden C, Murphy BJ. Identification of a Nonbasic Melanin Hormone Receptor 1 Antagonist as an Antiobesity Clinical Candidate. J Med Chem 2014; 57:7509-22. [DOI: 10.1021/jm500026w] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- William N. Washburn
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Mark Manfredi
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Pratik Devasthale
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Guohua Zhao
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Saleem Ahmad
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Andres Hernandez
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Jeffrey A. Robl
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Wei Wang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - James Mignone
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Zhenghua Wang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Khehyong Ngu
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Mary Ann Pelleymounter
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Daniel Longhi
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Rulin Zhao
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Bei Wang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Ning Huang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Neil Flynn
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Anthony V. Azzara
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Joel C. Barrish
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Kenneth Rohrbach
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - James J. Devenny
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Suzanne Rooney
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Michael Thomas
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Susan Glick
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Helen E. Godonis
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Susan J. Harvey
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Mary Jane Cullen
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Hongwei Zhang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Christian Caporuscio
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Paul Stetsko
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Mary Grubb
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Brad D. Maxwell
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Hong Yang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Atsu Apedo
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Brian Gemzik
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Evan B. Janovitz
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Christine Huang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Lisa Zhang
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Chris Freeden
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| | - Brian J. Murphy
- Metabolic Diseases Chemistry, ‡Metabolic Diseases Biology, §Preclinical Candidate
Optimization
Metabolism and Pharmacokinetics, ∥Discovery Chemistry Synthesis, ⊥Preclinical Candidate
Optimization Discovery Toxicology, #Preclinical Candidate Optimization Discovery Bioanalytical
Research, ∞Preclinical Candidate Optimization Biotransformation, ×Preclinical Candidate
Optimization Pharmaceutics, and ○Preclinical Candidate Optimization DAS SPS, Research and Development, Bristol-Myers Squibb Co., Princeton, New
| |
Collapse
|
14
|
Wu M, Li Y, Fu X, Wang J, Zhang S, Yang L. Profiling the interaction mechanism of quinoline/quinazoline derivatives as MCHR1 antagonists: an in silico method. Int J Mol Sci 2014; 15:15475-502. [PMID: 25257526 PMCID: PMC4200842 DOI: 10.3390/ijms150915475] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2014] [Revised: 06/30/2014] [Accepted: 08/19/2014] [Indexed: 12/13/2022] Open
Abstract
Melanin concentrating hormone receptor 1 (MCHR1), a crucial regulator of energy homeostasis involved in the control of feeding and energy metabolism, is a promising target for treatment of obesity. In the present work, the up-to-date largest set of 181 quinoline/quinazoline derivatives as MCHR1 antagonists was subjected to both ligand- and receptor-based three-dimensional quantitative structure–activity (3D-QSAR) analysis applying comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). The optimal predictable CoMSIA model exhibited significant validity with the cross-validated correlation coefficient (Q2) = 0.509, non-cross-validated correlation coefficient (R2ncv) = 0.841 and the predicted correlation coefficient (R2pred) = 0.745. In addition, docking studies and molecular dynamics (MD) simulations were carried out for further elucidation of the binding modes of MCHR1 antagonists. MD simulations in both water and lipid bilayer systems were performed. We hope that the obtained models and information may help to provide an insight into the interaction mechanism of MCHR1 antagonists and facilitate the design and optimization of novel antagonists as anti-obesity agents.
Collapse
Affiliation(s)
- Mingwei Wu
- Key Laboratory of Industrial Ecology and Environmental Engineering (MOE), Dalian University of Technology, Dalian 116024, China.
| | - Yan Li
- Key Laboratory of Industrial Ecology and Environmental Engineering (MOE), Dalian University of Technology, Dalian 116024, China.
| | - Xinmei Fu
- State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian 116024, China.
| | - Jinghui Wang
- Key Laboratory of Industrial Ecology and Environmental Engineering (MOE), Dalian University of Technology, Dalian 116024, China.
| | - Shuwei Zhang
- Key Laboratory of Industrial Ecology and Environmental Engineering (MOE), Dalian University of Technology, Dalian 116024, China.
| | - Ling Yang
- Laboratory of Pharmaceutical Resource Discovery, Dalian Institute of Chemical Physics, Graduate School of the Chinese Academy of Sciences, Dalian 116023, China.
| |
Collapse
|
15
|
The melanin-concentrating hormone receptors: neuronal and non-neuronal functions. INTERNATIONAL JOURNAL OF OBESITY SUPPLEMENTS 2014; 4:S31-6. [PMID: 27152164 DOI: 10.1038/ijosup.2014.9] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Melanin-concentrating hormone (MCH) is a cyclic peptide highly conserved in vertebrates and was originally identified as a skin-paling factor in Teleosts. In fishes, MCH also participates in the regulation of the stress-response and feeding behaviour. Mammalian MCH is a hypothalamic neuropeptide that displays multiple functions, mostly controlling feeding behaviour and energy homeostasis. Transgenic mouse models and pharmacological studies have shown the importance of the MCH system as a potential target in the treatment of appetite disorders and obesity as well as anxiety and psychiatric diseases. Two G-protein-coupled receptors (GPCRs) binding MCH have been characterized so far. The first, named MCH-R1 and also called SLC1, was identified through reverse pharmacology strategies by several groups as a cognate receptor of MCH. This receptor is expressed at high levels in many brain areas of rodents and primates and is also expressed in peripheral organs, albeit at a lower rate. A second receptor, designated MCH-R2, exhibited 38% identity to MCH-R1 and was identified by sequence analysis of the human genome. Interestingly, although MCH-R2 orthologues were also found in fishes, dogs, ferrets and non-human primates, this MCH receptor gene appeared either lacking or non-functional in rodents and lagomorphs. Both receptors are class I GPCRs, whose main roles are to mediate the actions of peptides and neurotransmitters in the central nervous system. However, examples of action of MCH on neuronal and non-neuronal cells are emerging that illustrate novel MCH functions. In particular, the functionality of endogenously expressed MCH-R1 has been explored in human neuroblastoma cells, SK-N-SH and SH-SY5Y cells, and in non-neuronal cell types such as the ependymocytes. Indeed, we have identified mitogen-activated protein kinase (MAPK)-dependent or calcium-dependent signalling cascades that ultimately contributed to neurite outgrowth in neuroblastoma cells or to modulation of ciliary beating in ependymal cells. The putative role of MCH on cellular shaping and plasticity on one side and volume transmission on the other must be now considered.
Collapse
|
16
|
Lim CJ, Lee HI, Kim N, Lee BH, Oh KS, Yi KY. 4-Aminophthalazin-1(2H)-one Derivatives as Melanin Concentrating Hormone Receptor 1 (MCH-R1) Antagonists. B KOREAN CHEM SOC 2013. [DOI: 10.5012/bkcs.2013.34.12.3851] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
17
|
Lim CJ, Kim JY, Lee BH, Oh KS, Yi KY. 2-Heteroaryl Benzimidazole Derivatives as Melanin Concentrating Hormone Receptor 1 (MCH-R1) Antagonists. B KOREAN CHEM SOC 2013. [DOI: 10.5012/bkcs.2013.34.8.2305] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
18
|
Lim CJ, Kim JY, Lee BH, Oh KS, Yi KY. Synthesis and SAR study of pyrrolo[3,4-b]pyridin-7(6H)-one derivatives as melanin concentrating hormone receptor 1 (MCH-R1) antagonists. Bioorg Med Chem Lett 2013; 23:1736-9. [PMID: 23411080 DOI: 10.1016/j.bmcl.2013.01.053] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2012] [Revised: 01/04/2013] [Accepted: 01/16/2013] [Indexed: 11/28/2022]
Abstract
The discovery and optimization of novel pyrrolo[3,4-b]pyridin-7(6H)-one MCH-R1 antagonists are described. A systematic SAR study probing the effects of aryl-, benzyl- and arylthio-substituents at the 2-position of the pyrrolo[3,4-b]pyridin-7(6H)-ones led to identification of the 2-[(4-fluorophenyl)thio] derivative 7b as a highly potent MCH-R1 antagonist. This compound also has favorable pharmacokinetic properties along with a high metabolic stability and a minimal impact on CYP isoforms and hERG.
Collapse
Affiliation(s)
- Chae Jo Lim
- Division of Drug Discovery Research, Korea Research Institute of Chemical Technology, Yuseong-gu, Daejeon 305-343, Republic of Korea
| | | | | | | | | |
Collapse
|
19
|
MacNeil DJ. The role of melanin-concentrating hormone and its receptors in energy homeostasis. Front Endocrinol (Lausanne) 2013; 4:49. [PMID: 23626585 PMCID: PMC3631741 DOI: 10.3389/fendo.2013.00049] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/22/2013] [Accepted: 04/09/2013] [Indexed: 01/25/2023] Open
Abstract
Extensive studies in rodents with melanin-concentrating hormone (MCH) have demonstrated that the neuropeptide hormone is a potent orexigen. Acutely, MCH causes an increase in food intake, while chronically it leads to increased weight gain, primarily as an increase in fat mass. Multiple knockout mice models have confirmed the importance of MCH in modulating energy homeostasis. Animals lacking MCH, MCH-containing neurons, or the MCH receptor all are resistant to diet-induced obesity. These genetic and pharmacologic studies have prompted a large effort to identify potent and selective MCH receptor antagonists, initially as tool compounds to probe pharmacology in models of obesity, with an ultimate goal to identify novel anti-obesity drugs. In animal models, MCH antagonists have consistently shown efficacy in reducing food intake acutely and inhibiting body-weight gain when given chronically. Five compounds have proceeded into clinical testing. Although they were reported as well-tolerated, none has advanced to long-term efficacy and safety studies.
Collapse
Affiliation(s)
- Douglas J. MacNeil
- Department of In Vitro Pharmacology, Merck Research LaboratoriesKenilworth, NJ, USA
- *Correspondence: Douglas J. MacNeil, Department of In Vitro Pharmacology, Merck Research Laboratories, K15-3-309D, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. e-mail:
| |
Collapse
|
20
|
Bingham M, Rankovic Z. Medicinal Chemistry Challenges in CNS Drug Discovery. DRUG DISCOVERY FOR PSYCHIATRIC DISORDERS 2012. [DOI: 10.1039/9781849734943-00465] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The human brain is a uniquely complex organ, which has evolved a sophisticated protection system to avoid injury from external insults and toxins. Penetrating the blood-brain barrier (BBB) to achieve the drug concentrations required for efficacious target receptor occupancy in the brain region of interest is a unique and significant challenge facing medicinal chemists working on CNS targets. Prospective design of molecules with optimal brain exposure and safety profile requires in-depth understanding of the fundamental relationships between physicochemical properties and in vitro and in vivo outcomes. Following from the now widely accepted “rule of five” guidelines for the design of oral drugs, the physicochemical properties for brain penetration have been extensively studied in an effort to define the characteristics of successful CNS drug candidates. Several key physicochemical properties have been identified that influence the rate of brain permeability and extent of brain penetration, including H-bonding potential, molecular weight, lipophilicity, polar surface area (PSA), ionization state and rotatable bond count. The ability to process this information effectively and engage in multi-parameter prospective design ultimately determines the success in delivering high-quality drug candidates that are suitable robustly to test hypotheses in the clinic and have good probability of reaching the market. This chapter focuses on the medicinal chemistry aspects of drug candidate optimization particular to the CNS therapeutic area, such as crossing the blood-brain barrier (BBB), as well as safety-related issues frequently challenging CNS programs such as hERG selectivity and phospholipidosis.
Collapse
Affiliation(s)
| | - Zoran Rankovic
- Eli Lilly and Company893 South Delaware Street, Indianapolis, IN
| |
Collapse
|
21
|
Högberg T, Frimurer TM, Sasmal PK. Melanin concentrating hormone receptor 1 (MCHR1) antagonists—Still a viable approach for obesity treatment? Bioorg Med Chem Lett 2012; 22:6039-47. [DOI: 10.1016/j.bmcl.2012.08.025] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2012] [Revised: 07/31/2012] [Accepted: 08/02/2012] [Indexed: 12/12/2022]
|
22
|
Lim CJ, Lee KE, Lee BH, Oh KS, Yi KY. 4-Heteroaryl Phthalazin-1(2H)-one Derivatives as Potent Melanin Concentrating Hormone Receptor 1 (MCH-R1) Antagonists. B KOREAN CHEM SOC 2012. [DOI: 10.5012/bkcs.2012.33.7.2389] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
23
|
Della-Zuana O, Audinot V, Levenez V, Ktorza A, Presse F, Nahon JL, Boutin JA. Peripheral injections of melanin-concentrating hormone receptor 1 antagonist S38151 decrease food intake and body weight in rodent obesity models. Front Endocrinol (Lausanne) 2012; 3:160. [PMID: 23267345 PMCID: PMC3527734 DOI: 10.3389/fendo.2012.00160] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2012] [Accepted: 11/26/2012] [Indexed: 12/02/2022] Open
Abstract
The compound S38151 is a nanomolar antagonist that acts at the melanin-concentrating hormone receptor 1 (MCH(1)). S38151 is more stable than its purely peptide counterpart, essentially because of the blockade of its N-terminus. Therefore, its action on various models of obesity was studied. Acute intra-cerebroventricular (i.c.v.) administration of S38151 in wild-type rats counteracted the effect of the stable precursor of melanin-concentrating hormone (MCH), NEI-MCH, in a dose-dependent manner (from 0.5 to 50 nmol/kg). In genetically obese Zucker fa/fa rats, daily i.c.v. administration of S38151 induced dose-dependent (5, 10, and 20 nmol/kg) inhibition of food intake, water intake, and body weight gain, as well as increased motility (maximal effect observed at 20 nmol/kg). In Zucker fa/fa rats, intraperitoneal injection of S38151 (30 mg/kg) induced complete inhibition of food consumption within 1 h. Daily intraperitoneal injection of S38151 (10 and 30 mg/kg) into genetically obese ob/ob mice or diet-induced obese mice is able to limit body weight gain. Furthermore, S38151 administration (10 and 30 mg/kg) does not affect food intake, water intake, or body weight gain in MCHR1-deleted mice, demonstrating that its effects are linked to its interaction with MCH(1). These results validate MCH(1) as a target of interest in obesity. S38151 cannot progress to the clinical phase because it is still too poorly stable in vivo.
Collapse
Affiliation(s)
- Odile Della-Zuana
- Maladies Métaboliques, Institut de Recherches SERVIERSuresnes, France
| | - Valérie Audinot
- Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches SERVIERCroissy-sur-Seine, France
| | - Viviane Levenez
- Maladies Métaboliques, Institut de Recherches SERVIERSuresnes, France
| | - Alain Ktorza
- Maladies Métaboliques, Institut de Recherches SERVIERSuresnes, France
| | - Françoise Presse
- Genomics and Evolution in Neuroendocrinology, Institut de Pharmacologie Moléculaire et Cellulaire, UMR7275, Centre National de la Recherche ScientifiqueValbonne, France
- Genomics and Evolution in Neuroendocrinology, Université de Nice Sophia AntipolisNice, France
| | - Jean-Louis Nahon
- Genomics and Evolution in Neuroendocrinology, Institut de Pharmacologie Moléculaire et Cellulaire, UMR7275, Centre National de la Recherche ScientifiqueValbonne, France
- Genomics and Evolution in Neuroendocrinology, Université de Nice Sophia AntipolisNice, France
| | - Jean A. Boutin
- Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches SERVIERCroissy-sur-Seine, France
- *Correspondence: Jean A. Boutin, Biotechnologie, Pharmacologie Moléculaire et Cellulaire, Institut de Recherches SERVIER, 125 chemin de Ronde, 78290 Croissy-sur-Seine, France. e-mail:
| |
Collapse
|
24
|
Kasai S, Kamaura M, Kamata M, Aso K, Ogino H, Nakano Y, Watanabe K, Kaisho T, Tawada M, Nagisa Y, Takekawa S, Kato K, Suzuki N, Ishihara Y. Melanin-concentrating hormone receptor 1 antagonists: synthesis, structure-activity relationship, docking studies, and biological evaluation of 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives. Bioorg Med Chem 2011; 19:6261-73. [PMID: 21975069 DOI: 10.1016/j.bmc.2011.09.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2011] [Revised: 09/05/2011] [Accepted: 09/06/2011] [Indexed: 11/20/2022]
Abstract
Melanin-concentrating hormone receptor 1 (MCHR1) antagonists have been studied as potential agents for the treatment of obesity. Initial structure-activity relationship studies of in-house hit compound 1a and subsequent optimization studies resulted in the identification of tetrahydroisoquinoline derivative 23, 1-(2-acetyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-[4-(4-chlorophenyl)piperidin-1-yl]butan-1-one, as a potent hMCHR1 antagonist. A homology model of hMCHR1 suggests that these compounds interact with Asn 294 and Asp 123 in the binding site of hMCHR1 to enhance binding affinity. Oral administration of compound 23 dose-dependently reduced food intake in diet-induced obesity (DIO)-F344 rats.
Collapse
Affiliation(s)
- Shizuo Kasai
- Pharmaceutical Research Division, Takeda Pharmaceutical Co., Ltd, 26-1 Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|